Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are common in NSCLC and are associated with low levels of tumor cell TS expression [17], suggesting that pemetrexed would be consistently effective against nonsquamous NSCLC with these genomic alterations. The gene discussed is ALK; the disease is non-small cell lung carcinoma.